A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients

Trial Profile

A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs Amoxicillin/omeprazole/rifabutin (Primary)
  • Indications Helicobacter pylori infections
  • Focus Registrational; Therapeutic Use
  • Acronyms ERADICATE-Hp
  • Sponsors RedHill Biopharma
  • Most Recent Events

    • 09 Jan 2017 Positive final results, announced in June 2015 of this trial were presented at the Innovations in Gastroenterology 2017 Symposium, according to a RedHill Biopharma media release.
    • 09 Jan 2017 Results published in the Media Release
    • 04 Jan 2017 According to a RedHill Biopharma media release, results will be presented at the Innovations in Gastroenterology 2017 Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top